Regulatory cascades of protein Phosphatases: Implications for Cancer treatment

Anti-Cancer Agents in Medicinal Chemistry

Volumn 11, Issue 1, 2011, Pages 64-77

  Jailkhani, Noor ^a   Chaudhri, Virendra K ^b   Rao, Kanury V S ^a  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cancer therapy; Combinatorial targeting; Kinase cascade; MAPK pathway; MKP1; MKP3; Phosphatase cascade; PP2A; Signaling network; Systems biology

Indexed keywords

ANTINEOPLASTIC AGENT; CALYCULIN A; CANTHARIDIN; CHELERYTHRINE; FOSTRIECIN; MICROCYSTIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NODULARIN; NSC 357756; NSC 95397; NU 126; OKADAIC ACID; PHOSPHOLIPASE C GAMMA; PHOSPHOPROTEIN PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE 1; PHOSPHOPROTEIN PHOSPHATASE 2A; PHOSPHOTRANSFERASE; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN KINASE C GAMMA; PROTEIN KINASE LYN; PSI 2106; RAC PROTEIN; RAF PROTEIN; SANGUINARINE; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CANCER THERAPY; DRUG TARGETING; ENZYME MECHANISM; ENZYME SUBSTRATE COMPLEX; EPIGENETICS; GENE MUTATION; HUMAN; NONHUMAN; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; REVIEW; SIGNAL PROCESSING; SIGNAL TRANSDUCTION;

EID: 79953018174     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152011794941253     Document Type: Review

References (145)

1. Kim, Y.; Gentry, M. S.; Harris, T. E.; Wiley, S. E.; Lawrence, J. C., Jr.; Dixon, J. E. A conserved phosphatase cascade that regulates nuclear membrane biogenesis. Proc. Natl. Acad. Sci. USA, 2007, 104 (16), 6596-6601.
2. Valjent, E.; Pascoli, V.; Svenningsson, P.; Paul, S.; Enslen, H.; Corvol, J. C.; Stipanovich, A.; Caboche, J.; Lombroso, P. J.; Nairn, A. C.; Greengard, P.; Herve, D.; Girault, J. A. Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. Proc. Natl. Acad. Sci. USA, 2005, 102 (2), 491-496.
3. Stipanovich, A.; Valjent, E.; Matamales, M.; Nishi, A.; Ahn, J. H.; Maroteaux, M.; Bertran-Gonzalez, J.; Brami-Cherrier, K.; Enslen, H.; Corbille, A. G.; Filhol, O.; Nairn, A. C.; Greengard, P.; Herve, D.; Girault, J. A. A phosphatase cascade by which rewarding stimuli control nucleosomal response. Nature, 2008, 453 (7197), 879-884.
4. Chaudhri, V. K.; Kumar, D.; Misra, M.; Dua, R.; Rao, K. V. Integration of a phosphatase cascade with the mitogen-activated protein kinase pathway provides for a novel signal processing function. J. Biol. Chem., 2010, 285 (2), 1296-1310.
5. Evan, G. I.; Vousden, K. H. Proliferation, cell cycle and apoptosis in cancer. Nature, 2001, 411 (6835), 342-348.
6. Kastan, M. B.; Bartek, J. Cell-cycle checkpoints and cancer. Nature, 2004, 432 (7015), 316-323.
7. Zetterberg, A.; Larsson, O.; Wiman, K. G. What is the restriction point? Curr. Opin. Cell Biol., 1995, 7 (6), 835-842.
8. Sullivan, M.; Morgan, D. O. Finishing mitosis, one step at a time. Nat. Rev. Mol. Cell Biol., 2007, 8 (11), 894-903.
9. Bollen, M.; Gerlich, D. W.; Lesage, B. Mitotic phosphatases: from entry guards to exit guides. Trends Cell Biol., 2009, 19 (10), 531-541.
10. Barabasi, A. L.; Oltvai, Z. N. Network biology: understanding the cell's functional organization. Nat. Rev. Genet., 2004, 5 (2), 101-113.
11. Papin, J. A.; Hunter, T.; Palsson, B. O.; Subramaniam, S. Reconstruction of cellular signalling networks and analysis of their properties. Nat. Rev. Mol. Cell Biol., 2005, 6 (2), 99-111.
12. Hartwell, L. H.; Hopfield, J. J.; Leibler, S.; Murray, A. W. From molecular to modular cell biology. Nature, 1999, 402 (6761 Suppl), C47-52.
13. Vermeulen, K.; Van Bockstaele, D. R.; Berneman, Z. N. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif., 2003, 36 (3), 131-149.
14. Hennessy, B. T.; Smith, D. L.; Ram, P. T.; Lu, Y.; Mills, G. B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov., 2005, 4 (12), 988-1004.
15. Downward, J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer, 2003, 3 (1), 11-22.
16. Bradham, C.; McClay, D. R. p38 MAPK in development and cancer. Cell Cycle, 2006, 5 (8), 824-828.
17. Cohen, P. The regulation of protein function by multisite phosphorylation-- a 25 year update. Trends Biochem. Sci., 2000, 25 (12), 596-601.
18. Shi, Y. Serine/threonine phosphatases: mechanism through structure. Cell, 2009, 139 (3), 468-484.
19. Alonso, A.; Sasin, J.; Bottini, N.; Friedberg, I.; Friedberg, I.; Osterman, A.; Godzik, A.; Hunter, T.; Dixon, J.; Mustelin, T. Protein tyrosine phosphatases in the human genome. Cell, 2004, 117 (6), 699-711.
20. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S. The protein kinase complement of the human genome. Science, 2002, 298 (5600), 1912-1934.
21. Lemmon, M. A.; Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell, 141 (7), 1117-1134.
22. Reya, T.; Clevers, H. Wnt signalling in stem cells and cancer. Nature, 2005, 434 (7035), 843-850.
23. Malumbres, M.; Barbacid, M. Cell cycle kinases in cancer. Curr. Opin. Genet. Dev., 2007, 17 (1), 60-65.
24. Malumbres, M.; Barbacid, M. Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer, 2009, 9 (3), 153-166.
25. Alon, U. Network motifs: theory and experimental approaches. Nat. Rev. Genet., 2007, 8 (6), 450-461.
26. Shoval, O.; Alon, U. SnapShot: network motifs. Cell, 2010, 143 (2), 326-e321.
27. Shiraishi, T.; Matsuyama, S.; Kitano, H. Large-scale analysis of network bistability for human cancers. PLoS Comput. Biol., 2010, 6 (7), e1000851.
28. Fitzgerald, J. B.; Schoeberl, B.; Nielsen, U. B.; Sorger, P. K. Systems biology and combination therapy in the quest for clinical efficacy. Nat. Chem. Biol., 2006, 2 (9), 458-466.
29. Lehar, J.; Stockwell, B. R.; Giaever, G.; Nislow, C. Combination chemical genetics. Nat. Chem. Biol., 2008, 4 (11), 674-681.
30. Keith, C. T.; Borisy, A. A.; Stockwell, B. R. Multicomponent therapeutics for networked systems. Nat. Rev. Drug Discov., 2005, 4 (1), 71-78.
31. Lehar, J.; Krueger, A.; Zimmermann, G.; Borisy, A. High-order combination effects and biological robustness. Mol. Syst. Biol., 2008, 4, 215.
32. Vogelstein, B.; Kinzler, K. W. Cancer genes and the pathways they control. Nat. Med., 2004, 10 (8), 789-799.
33. Kholodenko, B. N. Negative feedback and ultrasensitivity can bring about oscillations in the mitogen-activated protein kinase cascades. Eur. J. Biochem., 2000, 267 (6), 1583-1588.
34. Markevich, N. I.; Hoek, J. B.; Kholodenko, B. N. Signaling switches and bistability arising from multisite phosphorylation in protein kinase cascades. J. Cell Biol., 2004, 164 (3), 353-359.
35. Ceulemans, H.; Bollen, M. Functional diversity of protein phosphatase-1, a cellular economizer and reset button. Physiol. Rev., 2004, 84 (1), 1-39.
36. Virshup, D. M.; Shenolikar, S. From promiscuity to precision: protein phosphatases get a makeover. Mol. Cell, 2009, 33 (5), 537-545.
37. Heinrich, R.; Neel, B. G.; Rapoport, T. A. Mathematical models of protein kinase signal transduction. Mol. Cell, 2002, 9 (5), 957-970.
38. Hornberg, J. J.; Bruggeman, F. J.; Binder, B.; Geest, C. R.; de Vaate, A. J.; Lankelma, J.; Heinrich, R.; Westerhoff, H. V. Principles behind the multifarious control of signal transduction. ERK phosphorylation and kinase/phosphatase control. FEBS. J., 2005, 272 (1), 244-258.
39. Kumar, D.; Dua, R.; Srikanth, R.; Jayaswal, S.; Siddiqui, Z.; Rao, K. V. Cellular phosphatases facilitate combinatorial processing of receptor-activated signals. BMC Res. Notes, 2008, 1, 81.
40. Lindskog, M.; Kim, M.; Wikstrom, M. A.; Blackwell, K. T.; Kotaleski, J. H. Transient calcium and dopamine increase PKA activity and DARPP-32 phosphorylation. PLoS Comput. Biol., 2006, 2 (9), e119.
41. Moorhead, G. B.; Trinkle-Mulcahy, L.; Ulke-Lemee, A. Emerging roles of nuclear protein phosphatases. Nat. Rev. Mol. Cell Biol., 2007, 8 (3), 234-244.
42. Bollen, M.; Beullens, M. Signaling by protein phosphatases in the nucleus. Trends Cell Biol., 2002, 12 (3), 138-145.
43. Donzelli, M.; Draetta, G. F. Regulating mammalian checkpoints through Cdc25 inactivation. EMBO Rep., 2003, 4 (7), 671-677.
44. De Wulf, P.; Montani, F.; Visintin, R. Protein phosphatases take the mitotic stage. Curr. Opin. Cell Biol., 2009, 21 (6), 806-815.
45. Donzelli, M.; Squatrito, M.; Ganoth, D.; Hershko, A.; Pagano, M.; Draetta, G. F. Dual mode of degradation of Cdc25 A phosphatase. EMBO. J., 2002, 21 (18), 4875-4884.
46. Heneberg, P. Use of protein tyrosine phosphatase inhibitors as promising targeted therapeutic drugs. Curr. Med. Chem., 2009, 16 (6), 706-733.
47. Tonks, N. K. Protein tyrosine phosphatases: from genes, to function, to disease. Nat. Rev. Mol. Cell Biol., 2006, 7 (11), 833-846.
48. Ostman, A.; Hellberg, C.; Bohmer, F. D. Protein-tyrosine phosphatases and cancer. Nat. Rev. Cancer, 2006, 6 (4), 307-320.
49. Mumby, M. C.; Walter, G. Protein serine/threonine phosphatases: structure, regulation, and functions in cell growth. Physiol. Rev., 1993, 73 (4), 673-699.
50. Van Hoof, C.; Goris, J. PP2A fulfills its promises as tumor suppressor: which subunits are important? Cancer Cell, 2004, 5 (2), 105-106.
51. Franklin, C. C.; Kraft, A. S. Conditional expression of the mitogenactivated protein kinase (MAPK) phosphatase MKP-1 preferentially inhibits p38 MAPK and stress-activated protein kinase in U937 cells. J. Biol. Chem., 1997, 272 (27), 16917-16923.
52. Camps, M.; Nichols, A.; Arkinstall, S. Dual specificity phosphatases: a gene family for control of MAP kinase function. FASEB J., 2000, 14 (1), 6-16.
53. Farooq, A.; Zhou, M. M. Structure and regulation of MAPK phosphatases. Cell Signal., 2004, 16 (7), 769-779.
54. Sarkozi, R.; Miller, B.; Pollack, V.; Feifel, E.; Mayer, G.; Sorokin, A.; Schramek, H. ERK1/2-driven and MKP-mediated inhibition of EGF-induced ERK5 signaling in human proximal tubular cells. J.Cell Physiol., 2007, 211 (1), 88-100.
55. Loda, M.; Capodieci, P.; Mishra, R.; Yao, H.; Corless, C.; Grigioni, W.; Wang, Y.; Magi-Galluzzi, C.; Stork, P. J. Expression of mitogen- activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis. Am. J. Pathol., 1996, 149 (5), 1553-1564.
56. Boutros, T.; Chevet, E.; Metrakos, P. Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation: roles in cell growth, death, and cancer. Pharmacol. Rev., 2008, 60 (3), 261-310.
57. Bang, Y. J.; Kwon, J. H.; Kang, S. H.; Kim, J. W.; Yang, Y. C. Increased MAPK activity and MKP-1 overexpression in human gastric adenocarcinoma. Biochem. Biophys. Res. Commun., 1998, 250 (1), 43-47.
58. Groom, L. A.; Sneddon, A. A.; Alessi, D. R.; Dowd, S.; Keyse, S. M. Differential regulation of the MAP, SAP and RK/p38 kinases by Pyst1, a novel cytosolic dual-specificity phosphatase. EMBO. J., 1996, 15 (14), 3621-3632.
59. Muda, M.; Boschert, U.; Dickinson, R.; Martinou, J. C.; Martinou, I.; Camps, M.; Schlegel, W.; Arkinstall, S. MKP-3, a novel cytosolic protein-tyrosine phosphatase that exemplifies a new class of mitogen- activated protein kinase phosphatase. J. Biol. Chem., 1996, 271 (8), 4319-4326.
60. Furukawa, T.; Fujisaki, R.; Yoshida, Y.; Kanai, N.; Sunamura, M.; Abe, T.; Takeda, K.; Matsuno, S.; Horii, A. Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas. Mod. Pathol., 2005, 18 (8), 1034-1042.
61. Xu, S.; Furukawa, T.; Kanai, N.; Sunamura, M.; Horii, A. Abrogation of DUSP6 by hypermethylation in human pancreatic cancer. J. Hum. Genet., 2005, 50 (4), 159-167.
62. Okudela, K.; Yazawa, T.; Woo, T.; Sakaeda, M.; Ishii, J.; Mitsui, H.; Shimoyamada, H.; Sato, H.; Tajiri, M.; Ogawa, N.; Masuda, M.; Takahashi, T.; Sugimura, H.; Kitamura, H. Down-regulation of DUSP6 expression in lung cancer: its mechanism and potential role in carcinogenesis. Am. J. Pathol., 2009, 175 (2), 867-881.
63. Warmka, J. K.; Mauro, L. J.; Wattenberg, E. V. Mitogen-activated protein kinase phosphatase-3 is a tumor promoter target in initiated cells that express oncogenic Ras. J. Biol. Chem., 2004, 279 (32), 33085-33092.
64. Zhang, Z.; Kobayashi, S.; Borczuk, A. C.; Leidner, R. S.; Laframboise, T.; Levine, A. D.; Halmos, B. Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells. Carcinogenesis., 2010, 31 (4), 577-586.
65. Zeliadt, N. A.; Mauro, L. J.; Wattenberg, E. V. Reciprocal regulation of extracellular signal regulated kinase 1/2 and mitogen activated protein kinase phosphatase-3. Toxicol. Appl. Pharmacol., 2008, 232 (3), 408-417.
66. Virshup, D. M. Protein phosphatase 2A: a panoply of enzymes. Curr. Opin. Cell Biol., 2000, 12 (2), 180-185.
67. Wera, S.; Hemmings, B. A. Serine/threonine protein phosphatases. Biochem. J., 1995, 311 (Pt 1), 17-29.
68. Janssens, V.; Goris, J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem. J., 2001, 353 (Pt 3), 417-439.
69. Neviani, P.; Santhanam, R.; Trotta, R.; Notari, M.; Blaser, B. W.; Liu, S.; Mao, H.; Chang, J. S.; Galietta, A.; Uttam, A.; Roy, D. C.; Valtieri, M.; Bruner-Klisovic, R.; Caligiuri, M. A.; Bloomfield, C. D.; Marcucci, G.; Perrotti, D. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell, 2005, 8 (5), 355-368.
70. Ory, S.; Zhou, M.; Conrads, T. P.; Veenstra, T. D.; Morrison, D. K. Protein phosphatase 2A positively regulates Ras signaling by dephosphorylating KSR1 and Raf-1 on critical 14-3-3 binding sites. Curr. Biol., 2003, 13 (16), 1356-1364.
71. Ratcliffe, M. J.; Itoh, K.; Sokol, S. Y. A positive role for the PP2A catalytic subunit in Wnt signal transduction. J. Biol. Chem., 2000, 275 (46), 35680-35683.
72. McConnell, J. L.; Wadzinski, B. E. Targeting protein serine/ threonine phosphatases for drug development. Mol. Pharmacol., 2009, 75 (6), 1249-1261.
73. Neviani, P.; Santhanam, R.; Oaks, J. J.; Eiring, A. M.; Notari, M.; Blaser, B. W.; Liu, S.; Trotta, R.; Muthusamy, N.; Gambacorti- Passerini, C.; Druker, B. J.; Cortes, J.; Marcucci, G.; Chen, C. S.; Verrills, N. M.; Roy, D. C.; Caligiuri, M. A.; Bloomfield, C. D.; Byrd, J. C.; Perrotti, D. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome- positive acute lymphocytic leukemia. J. Clin. Invest., 2007, 117 (9), 2408-2421.
74. Boutros, R.; Lobjois, V.; Ducommun, B. CDC25 phosphatases in cancer cells: key players? Good targets? Nat. Rev. Cancer, 2007, 7 (7), 495-507.
75. Margolis, S. S.; Perry, J. A.; Forester, C. M.; Nutt, L. K.; Guo, Y.; Jardim, M. J.; Thomenius, M. J.; Freel, C. D.; Darbandi, R.; Ahn, J. H.; Arroyo, J. D.; Wang, X. F.; Shenolikar, S.; Nairn, A. C.; Dunphy, W. G.; Hahn, W. C.; Virshup, D. M.; Kornbluth, S. Role for the PP2A/B56delta phosphatase in regulating 14-3-3 release from Cdc25 to control mitosis. Cell, 2006, 127 (4), 759-773.
76. Graves, P. R.; Lovly, C. M.; Uy, G. L.; Piwnica-Worms, H. Localization of human Cdc25C is regulated both by nuclear export and 14-3-3 protein binding. Oncogene, 2001, 20 (15), 1839-1851.
77. Margolis, S. S.; Walsh, S.; Weiser, D. C.; Yoshida, M.; Shenolikar, S.; Kornbluth, S. PP1 control of M phase entry exerted through 14-3-3-regulated Cdc25 dephosphorylation. EMBO. J., 2003, 22 (21), 5734-5745.
78. Chen, F.; Zhang, Z.; Bower, J.; Lu, Y.; Leonard, S. S.; Ding, M.; Castranova, V.; Piwnica-Worms, H.; Shi, X. Arsenite-induced Cdc25C degradation is through the KEN-box and ubiquitinproteasome pathway. Proc. Natl. Acad. Sci. USA, 2002, 99 (4), 1990-1995.
79. Bulavin, D. V.; Higashimoto, Y.; Demidenko, Z. N.; Meek, S.; Graves, P.; Phillips, C.; Zhao, H.; Moody, S. A.; Appella, E.; Piwnica- Worms, H.; Fornace, A. J., Jr. Dual phosphorylation controls Cdc25 phosphatases and mitotic entry. Nat. Cell Biol., 2003, 5 (6), 545-551.
80. Wang, R.; He, G.; Nelman-Gonzalez, M.; Ashorn, C. L.; Gallick, G. E.; Stukenberg, P. T.; Kirschner, M. W.; Kuang, J. Regulation of Cdc25C by ERK-MAP kinases during the G2/M transition. Cell, 2007, 128 (6), 1119-1132.
81. Toyoshima-Morimoto, F.; Taniguchi, E.; Nishida, E. Plk1 promotes nuclear translocation of human Cdc25C during prophase. EMBO Rep., 2002, 3 (4), 341-348.
82. Izumi, T.; Maller, J. L. Elimination of cdc2 phosphorylation sites in the cdc25 phosphatase blocks initiation of M-phase. Mol. Biol. Cell, 1993, 4 (12), 1337-1350.
83. Hoffmann, I.; Clarke, P. R.; Marcote, M. J.; Karsenti, E.; Draetta, G. Phosphorylation and activation of human cdc25-C by cdc2-- cyclin B and its involvement in the self-amplification of MPF at mitosis. EMBO. J., 1993, 12 (1), 53-63.
84. Karlsson-Rosenthal, C.; Millar, J. B. Cdc25: mechanisms of checkpoint inhibition and recovery. Trends Cell Biol., 2006, 16 (6), 285-292.
85. Myer, D. L.; Bahassi el, M.; Stambrook, P. J. The Plk3-Cdc25 circuit. Oncogene, 2005, 24 (2), 299-305.
86. Blethrow, J. D.; Glavy, J. S.; Morgan, D. O.; Shokat, K. M. Covalent capture of kinase-specific phosphopeptides reveals Cdk1- cyclin B substrates. Proc. Natl. Acad. Sci. USA, 2008, 105 (5), 1442-1447.
87. Chi, Y.; Welcker, M.; Hizli, A. A.; Posakony, J. J.; Aebersold, R.; Clurman, B. E. Identification of CDK2 substrates in human cell lysates. Genome Biol., 2008, 9 (10), R149.
88. Guo, C. Y.; Brautigan, D. L.; Larner, J. M. Ionizing radiation activates nuclear protein phosphatase-1 by ATM-dependent dephosphorylation. J. Biol. Chem., 2002, 277 (44), 41756-41761.
89. Liu, C. W.; Wang, R. H.; Dohadwala, M.; Schonthal, A. H.; Villa- Moruzzi, E.; Berndt, N. Inhibitory phosphorylation of PP1alpha catalytic subunit during the G(1)/S transition. J Biol. Chem., 1999, 274 (41), 29470-29475.
90. Wu, J. Q.; Guo, J. Y.; Tang, W.; Yang, C. S.; Freel, C. D.; Chen, C.; Nairn, A. C.; Kornbluth, S. PP1-mediated dephosphorylation of phosphoproteins at mitotic exit is controlled by inhibitor-1 and PP1 phosphorylation. Nat. Cell Biol., 2009, 11 (5), 644-651.
91. Chen, J.; Martin, B. L.; Brautigan, D. L. Regulation of protein serine-threonine phosphatase type-2A by tyrosine phosphorylation. Science, 1992, 257 (5074), 1261-1264.
92. Finnegan, S.; Mackey, A. M.; Cotter, T. G. A stress survival response in retinal cells mediated through inhibition of the serine/threonine phosphatase PP2A. Eur. J. Neurosci., 2010, 32 (3), 322-334.
93. Ravichandran, L. V.; Chen, H.; Li, Y.; Quon, M. J. Phosphorylation of PTP1B at Ser(50) by Akt impairs its ability to dephosphorylate the insulin receptor. Mol. Endocrinol., 2001, 15 (10), 1768-1780.
94. Dupre, K. B. A potential neuroanatomical dissociation of DARPP-32 in striatal ERK signaling. J. Neurosci., 2008, 28 (43), 10783-10785.
95. Le Novere, N.; Li, L.; Girault, J. A. DARPP-32: molecular integration of phosphorylation potential. Cell Mol. Life Sci., 2008, 65 (14), 2125-2127.
96. Reis, H. J.; Rosa, D. V.; Guimaraes, M. M.; Souza, B. R.; Barros, A. G.; Pimenta, F. J.; Souza, R. P.; Torres, K. C.; Romano-Silva, M. A. Is DARPP-32 a potential therapeutic target? Expert Opin. Ther. Targets, 2007, 11 (12), 1649-1661.
97. Seger, R.; Krebs, E. G. The MAPK signaling cascade. FASEB J, 1995, 9 (9), 726-735.
98. Pearson, G.; Robinson, F.; Beers Gibson, T.; Xu, B. E.; Karandikar, M.; Berman, K.; Cobb, M. H. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr. Rev., 2001, 22 (2), 153-183.
99. Chang, L.; Karin, M. Mammalian MAP kinase signalling cascades. Nature, 2001, 410 (6824), 37-40.
100. Wada, T.; Penninger, J. M. Mitogen-activated protein kinases in apoptosis regulation. Oncogene, 2004, 23 (16), 2838-2849.
101. Dhillon, A. S.; Hagan, S.; Rath, O.; Kolch, W. MAP kinase signalling pathways in cancer. Oncogene, 2007, 26 (22), 3279-3290.
102. Roberts, P. J.; Der, C. J. Targeting the Raf-MEK-ERK mitogenactivated protein kinase cascade for the treatment of cancer. Oncogene, 2007, 26 (22), 3291-3310.
103. Levchenko, A.; Bruck, J.; Sternberg, P. W. Scaffold proteins may biphasically affect the levels of mitogen-activated protein kinase signaling and reduce its threshold properties. Proc. Natl. Acad. Sci. USA, 2000, 97 (11), 5818-5823.
104. Komatsuzaki, S.; Aoki, Y.; Niihori, T.; Okamoto, N.; Hennekam, R. C.; Hopman, S.; Ohashi, H.; Mizuno, S.; Watanabe, Y.; Kamasaki, H.; Kondo, I.; Moriyama, N.; Kurosawa, K.; Kawame, H.; Okuyama, R.; Imaizumi, M.; Rikiishi, T.; Tsuchiya, S.; Kure, S.; Matsubara, Y. Mutation analysis of the SHOC2 gene in Noonanlike syndrome and in hematologic malignancies. J. Hum. Genet., 2010, 55 (12), 801-809.
105. Nazarian, R.; Shi, H.; Wang, Q.; Kong, X.; Koya, R. C.; Lee, H.; Chen, Z.; Lee, M. K.; Attar, N.; Sazegar, H.; Chodon, T.; Nelson, S. F.; McArthur, G.; Sosman, J. A.; Ribas, A.; Lo, R. S. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or NRAS upregulation. Nature., 2010, 468 (7326), 973-977.
106. Kolch, W.; Calder, M.; Gilbert, D. When kinases meet mathematics: the systems biology of MAPK signalling. FEBS Lett., 2005, 579 (8), 1891-1895.
107. Blenis, J. Signal transduction via the MAP kinases: proceed at your own RSK. Proc Natl Acad Sci USA, 1993, 90 (13), 5889-5892.
108. Cobb, M. H.; Goldsmith, E. J. How MAP kinases are regulated. J. Biol. Chem., 1995, 270 (25), 14843-14846.
109. Orton, R. J.; Sturm, O. E.; Vyshemirsky, V.; Calder, M.; Gilbert, D. R.; Kolch, W. Computational modelling of the receptortyrosine-kinase-activated MAPK pathway. Biochem. J., 2005, 392 (Pt 2), 249-261.
110. Yoshioka, K. Scaffold proteins in mammalian MAP kinase cascades. J. Biochem., 2004, 135 (6), 657-661.
111. Lin, J.; Harding, A.; Giurisato, E.; Shaw, A. S. KSR1 modulates the sensitivity of mitogen-activated protein kinase pathway activation in T cells without altering fundamental system outputs. Mol. Cell Biol., 2009, 29 (8), 2082-2091.
112. Altan-Bonnet, G.; Germain, R. N. Modeling T cell antigen discrimination based on feedback control of digital ERK responses. PLoS Biol., 2005, 3 (11), e356.
113. Saxena, M.; Mustelin, T. Extracellular signals and scores of phosphatases: all roads lead to MAP kinase. Semin. Immunol., 2000, 12 (4), 387-396.
114. Theodosiou, A.; Ashworth, A. MAP kinase phosphatases. Genome Biol., 2002, 3 (7), REVIEWS3009.
115. Bhalla, U. S.; Ram, P. T.; Iyengar, R. MAP kinase phosphatase as a locus of flexibility in a mitogen-activated protein kinase signaling network. Science, 2002, 297 (5583), 1018-1023.
116. Dickinson, R. J.; Keyse, S. M. Diverse physiological functions for dual-specificity MAP kinase phosphatases. J. Cell Sci., 2006, 119 (Pt 22), 4607-4615.
117. Huang, C. Y.; Ferrell, J. E., Jr. Ultrasensitivity in the mitogenactivated protein kinase cascade. Proc. Natl. Acad. Sci. USA, 1996, 93 (19), 10078-10083.
118. Eungdamrong, N. J.; Iyengar, R. Compartment-specific feedback loop and regulated trafficking can result in sustained activation of Ras at the Golgi. Biophys. J., 2007, 92 (3), 808-815.
119. Qiao, L.; Nachbar, R. B.; Kevrekidis, I. G.; Shvartsman, S. Y. Bistability and oscillations in the Huang-Ferrell model of MAPK signaling. PLoS Comput. Biol., 2007, 3 (9), 1819-1826.
120. Das, J.; Ho, M.; Zikherman, J.; Govern, C.; Yang, M.; Weiss, A.; Chakraborty, A. K.; Roose, J. P. Digital signaling and hysteresis characterize ras activation in lymphoid cells. Cell, 2009, 136 (2), 337-351.
121. Bluthgen, N.; Bruggeman, F. J.; Legewie, S.; Herzel, H.; Westerhoff, H. V.; Kholodenko, B. N. Effects of sequestration on signal transduction cascades. FEBS. J., 2006, 273 (5), 895-906.
122. Locasale, J. W.; Shaw, A. S.; Chakraborty, A. K. Scaffold proteins confer diverse regulatory properties to protein kinase cascades. Proc Natl Acad Sci USA, 2007, 104 (33), 13307-13312.
123. Stoker, A. W. Protein tyrosine phosphatases and signalling. J. Endocrinol., 2005, 185 (1), 19-33.
124. Rajakulendran, T.; Sahmi, M.; Lefrancois, M.; Sicheri, F.; Therrien, M. A dimerization-dependent mechanism drives RAF catalytic activation. Nature, 2009, 461 (7263), 542-545.
125. Schubbert, S.; Shannon, K.; Bollag, G. Hyperactive Ras in developmental disorders and cancer. Nat. Rev. Cancer, 2007, 7 (4), 295-308.
126. Vigil, D.; Cherfils, J.; Rossman, K. L.; Der, C. J. Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat. Rev. Cancer, 2010, 10 (12), 842-857.
127. Keyse, S. M. Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev., 2008, 27 (2), 253-261.
128. Weinstein, I. B.; Joe, A. Oncogene addiction. Cancer Res., 2008, 68 (9), 3077-3080; discussion 3080.
129. Castelli, M.; Camps, M.; Gillieron, C.; Leroy, D.; Arkinstall, S.; Rommel, C.; Nichols, A. MAP kinase phosphatase 3 (MKP3) interacts with and is phosphorylated by protein kinase CK2alpha. J. Biol. Chem., 2004, 279 (43), 44731-44739.
130. Zimmermann, G. R.; Lehar, J.; Keith, C. T. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov. Today, 2007, 12 (1-2), 34-42.
131. Cohen, A. A.; Geva-Zatorsky, N.; Eden, E.; Frenkel-Morgenstern, M.; Issaeva, I.; Sigal, A.; Milo, R.; Cohen-Saidon, C.; Liron, Y.; Kam, Z.; Cohen, L.; Danon, T.; Perzov, N.; Alon, U. Dynamic proteomics of individual cancer cells in response to a drug. Science, 2008, 322 (5907), 1511-1516.
132. Glatter, T.; Wepf, A.; Aebersold, R.; Gstaiger, M. An integrated workflow for charting the human interaction proteome: insights into the PP2A system. Mol. Syst. Biol., 2009, 5, 237.
133. Lin, C. F.; Chen, C. L.; Chiang, C. W.; Jan, M. S.; Huang, W. C.; Lin, Y. S. GSK-3beta acts downstream of PP2A and the PI 3- kinase-Akt pathway, and upstream of caspase-2 in ceramideinduced mitochondrial apoptosis. J. Cell Sci., 2007, 120 (Pt 16), 2935-2943.
134. Ugi, S.; Imamura, T.; Maegawa, H.; Egawa, K.; Yoshizaki, T.; Shi, K.; Obata, T.; Ebina, Y.; Kashiwagi, A.; Olefsky, J. M. Protein phosphatase 2A negatively regulates insulin's metabolic signaling pathway by inhibiting Akt (protein kinase B) activity in 3T3-L1 adipocytes. Mol. Cell Biol., 2004, 24 (19), 8778-8789.
135. Shanley, T. P.; Vasi, N.; Denenberg, A.; Wong, H. R. The serine/ threonine phosphatase, PP2A: endogenous regulator of inflammatory cell signaling. J. Immunol., 2001, 166 (2), 966-972.
136. Junttila, M. R.; Li, S. P.; Westermarck, J. Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. FASEB. J., 2008, 22 (4), 954-965.
137. Vogt, A.; McDonald, P. R.; Tamewitz, A.; Sikorski, R. P.; Wipf, P.; Skoko, J. J., 3rd; Lazo, J. S. A cell-active inhibitor of mitogenactivated protein kinase phosphatases restores paclitaxel-induced apoptosis in dexamethasone-protected cancer cells. Mol. Cancer Ther., 2008, 7 (2), 330-340.
138. Lazo, J. S.; Nunes, R.; Skoko, J. J.; Queiroz de Oliveira, P. E.; Vogt, A.; Wipf, P. Novel benzofuran inhibitors of human mitogenactivated protein kinase phosphatase-1. Bioorg. Med. Chem., 2006, 14 (16), 5643-5650.
139. Vogt, A.; Cooley, K. A.; Brisson, M.; Tarpley, M. G.; Wipf, P.; Lazo, J. S. Cell-active dual specificity phosphatase inhibitors identified by high-content screening. Chem. Biol., 2003, 10 (8), 733-742.
140. Vogt, A.; Tamewitz, A.; Skoko, J.; Sikorski, R. P.; Giuliano, K. A.; Lazo, J. S. The benzo[c]phenanthridine alkaloid, sanguinarine, is a selective, cell-active inhibitor of mitogen-activated protein kinase phosphatase-1. J. Biol. Chem., 2005, 280 (19), 19078-19086.
141. Lazo, J. S.; Skoko, J. J.; Werner, S.; Mitasev, B.; Bakan, A.; Koizumi, F.; Yellow-Duke, A.; Bahar, I.; Brummond, K. M. Structurally unique inhibitors of human mitogen-activated protein kinase phosphatase-1 identified in a pyrrole carboxamide library. J. Pharmacol. Exp. Ther., 2007, 322 (3), 940-947.
142. Ishihara, H.; Martin, B. L.; Brautigan, D. L.; Karaki, H.; Ozaki, H.; Kato, Y.; Fusetani, N.; Watabe, S.; Hashimoto, K.; Uemura, D.; Hartshorne, D. J. Calyculin A and okadaic acid: inhibitors of protein phosphatase activity. Biochem. Biophys. Res. Commun., 1989, 159 (3), 871-877.
143. Lewy, D. S.; Gauss, C. M.; Soenen, D. R.; Boger, D. L. Fostriecin: chemistry and biology. Curr. Med. Chem., 2002, 9 (22), 2005-2032.
144. Honkanen, R. E.; Zwiller, J.; Moore, R. E.; Daily, S. L.; Khatra, B. S.; Dukelow, M.; Boynton, A. L. Characterization of microcystin- LR, a potent inhibitor of type 1 and type 2A protein phosphatases. J. Biol.Chem., 1990, 265 (32), 19401-19404.
145. Honkanen, R. E.; Dukelow, M.; Zwiller, J.; Moore, R. E.; Khatra, B. S.; Boynton, A. L. Cyanobacterial nodularin is a potent inhibitor of type 1 and type 2A protein phosphatases. Mol. Pharmacol., 1991, 40 (4), 577-583.